Kenneth J. Hillan

Biography

  Dr. Hillan joined Achaogen in 2011 as Chief Medical Officer and was appointed Chief Executive Officer and a member of its board of directors in October 2011. Prior to joining Achaogen, from August 1994 to April 2011, Dr. Hillan served at Genentech, Inc. (acquired by Roche in 2009), a pharmaceutical company. Dr. Hillan was responsible for numerous successful drug approvals and led the medical and scientific strategies for its Immunology, Tissue Growth and Repair drug portfolio. He served in a number of key leadership positions in research and development, including Senior Vice President Clinical Development, Inflammation, Vice President Immunology, Tissue Growth and Repair (ITGR), Vice President Development Sciences and Vice President Research Operations and Pathology. Dr. Hillan also previously served as Senior Vice President and head of Clinical Development and Product Development Strategy in Asia-Pacific for Roche in Shanghai, China. Dr. Hillan currently serves on the board of directors of Zymeworks, Inc., and he served on the board of directors of Relypsa, Inc. from 2014 until 2016, when it was acquired by Galenica AG.  

Research Interest

 Pharmaceutical